When exploring mechanisms related to tumor microenvironment role in endocrine-independent HER-2 negative breast cancer antiangiogenic activity (Hsu et al., 2020; Zunica et al., 2021), metabolism shift (Lin et al., 2019; Zhao et al., 2020; 2021; Deng et al., 2021; Chen et al., 2022; Fouzat et al., 2022; Lv et al., 2022) and immunomodulation (Guerra et al., 2021; Yang et al., 2021; Chen et al., 2022; Ke et al., 2022) (Figure 2) are presented. The gene discussed is ERBB2; the disease is breast cancer.